Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.48 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.42 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PPARG | P37231 | 1/20 | 0.33 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1343169 | 0.83 | DYRK1A (0.42) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL102473 | 0.83 | CYP1A2 (0.59) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| Ethane SCHEMBL2154002 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL28349620 | 0.80 | CYP1A2 (0.57) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL28227844 | 0.79 | CYP1A2 (0.38) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL1003690 | 0.74 | TSHR (0.62) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL769669 | 0.74 | DYRK1A (0.46) | ALDH1A1TSHRLMNADYRK1AKDM4E | |
| SCHEMBL30485186 | 0.74 | TSHR (0.62) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL17796263 | 0.74 | CYP1A2 (0.52) | CYP1A2CYP2C19ALDH1A1TSHRLMNA | |
| SCHEMBL26955887 | 0.74 | ALDH1A1 (0.38) | ALDH1A1LMNADYRK1AKDM4ESMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3845515-B1 | PRODUCTION METHOD FOR CRYSTAL OF REDUCED COENZYME Q10 HAVING EXCELLENT STABILITY | KANEKA CORP (JP) | 2025-11-12 | — | — | EP | disclosed |
| WO-2025132946-A1 | PHENYLPYRROLIDINE DERIVATIVES AND THEIR USE AS POI-THETA DERIVATIVES | BREAKPOINT THERAPEUTICS GMBH (DE) | 2025-06-26 | — | — | WO | disclosed |
| CN-112839921-B | Process for producing reduced coenzyme Q10 crystals having excellent stability | 株式会社钟化 | 2024-02-20 | — | — | CN | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | QURIENT CO., LTD. (KR) | 2024-01-02 | — | — | US | disclosed |
| WO-2023214325-A1 | PYRAZOLOPYRIMIDINE DERIVATIVES AND USES THEREOF AS TET2 INHIBITORS | NOVARTIS AG (CH) | 2023-11-09 | — | — | WO | disclosed |
| US-11773043-B2 | Systems and methods for producing coenzyme Q10 | Inner Mongolia Kingdomway Pharmaceutical Co., Ltd. (CN) | 2023-10-03 | — | — | US | disclosed |
| CN-115484903-A | Device for the secretion of tears | 株式会社普欧威盖特 | 2022-12-16 | — | — | CN | disclosed |
| US-11498893-B2 | Production method for crystal of reduced coenzyme Q10 having excellent stability | KANEKA CORPORATION (JP) | 2022-11-15 | — | — | US | disclosed |
| US-11453633-B2 | Production method for crystal of reduced coenzyme Q10 having excellent stability | KANEKA CORPORATION (JP) | 2022-09-27 | — | — | US | disclosed |
| WO-2006058993-A1 | ARYLPIPERAZINE DERIVATIVES AND THEIR USE AS LIGANDS SELECTIVE OF THE DOPAMINE D3 RECEPTOR | BIOPROJET (FR) | 2006-06-08 | — | — | WO | disclosed |
| WO-2006055951-A2 | TETRAHYDROISOQUINOLINES AS FACTOR XA INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2006-05-26 | — | — | WO | disclosed |
| US-6906075-B2 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORP. (US) | 2005-06-14 | — | — | US | disclosed |
| EP-1465888-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004033455-A2 | HEMISUCCINATE SALTS OF HETEROCYCLIC DPP-IV INHIBITORS | NOVO NORDISK A/S (DK) | 2004-04-22 | — | — | WO | disclosed |
| EP-1404675-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2004-04-07 | — | — | EP | disclosed |
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | NEUROGEN CORPORATION | 2003-11-20 | — | — | US | disclosed |
| WO-2003059289-A2 | MELANIN CONCENTRATING HORMONE RECEPTOR LIGANDS: SUBSTITUTED BENZOIMIDAZOLE ANALOGUES | NEUROGEN CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |
| WO-2003004496-A1 | DPP-IV-INHIBITING PURINE DERIVATIVES FOR THE TREATMENT OF DIABETES | NOVO NORDISK A/S (DK) | 2003-01-16 | — | — | WO | disclosed |
| US-4244966-A | 1,3-Dihydro-3-(2-hydroxy-, 2-bromo- or 2-chloroethyl)-2H-isoindol-1-one derivatives | AMERICAN HOME PRODUCTS CORPORATION (US) | 1981-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216390-A1 | Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues | MCHR1, MCHR2, MC1R | CYP1A2 585/4885CYP2C19 467/4885ALDH1A1 1474/4885 |
| US-11858937-B2 | Substituted pyrazolo[1,5-a]pyrimidines and pyrazolo[1,5-a][1,3,5]triazines as CDK inhibitors | CDKL5, CDK15, CDK5 | CYP1A2 853/4885CYP2C19 475/4885ALDH1A1 916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.